A study presented at the San Antonio Breast Cancer Symposium 2023 reveals that many patients with ductal carcinoma in situ (DCIS) may not require radiotherapy as part of their treatment. Researchers conducted a study using a 12-gene assay called the DCIS score (DS) to assess patients’ risk levels. The study findings suggest that patients with low-risk DS profiles can safely forgo radiotherapy, reducing treatment burden and potential side effects. The research provides a promising approach for individualizing treatment plans and sparing patients unnecessary radiation therapy. This study could have significant implications for the management of DCIS, potentially leading to better outcomes and improved quality of life for patients. Further research and validation studies are needed to confirm these findings and establish guidelines for clinical practice based on the DS score.
Research Shows Some Ductal Carcinoma Patients May Not Need Radiotherapy
New research suggests that radiotherapy may not be necessary for many patients with ductal carcinoma in situ (DCIS), according to a study presented at the San Antonio Breast Cancer Symposium 2023. The study found that a 12-gene assay called the DCIS score (DS) can help identify patients who can safely forgo radiotherapy, reducing treatment burden and potential side effects.
Latest from Blog
Manu Chopra, CEO of Karya Inc., emphasized the importance of utilizing artificial intelligence (AI) to reduce
Italy has decided to withdraw from China's Belt and Road Initiative, becoming the only G7 nation
Zerodha's top executives collectively received a remuneration of about ₹200 crore in the financial year 2022-23,
The US Space Force's X-37B space plane is gearing up for its seventh mission, after landing
Ocean water is much more complex and diverse than it may seem at first glance. From
